Concentric Medical Announces Key International Regulatory Approvals of Its Trevo(TM) System

MOUNTAIN VIEW, California, February 10 - Concentric Medical, Inc., the global leader in acute ischemic stroke
intervention, today announced that its Trevo System for acute ischemic stroke
has received regulatory approval in both Europe (CE Mark) and Canada.

Leading EU centers began initial clinical evaluation of the Trevo System
following receipt of CE Mark in late 2009. Numerous cases have been performed
and early clinical feedback continues to be positive.

Maria Sainz, President and CEO of Concentric Medical, said, "I am
thrilled Concentric has received these approvals and that physician feedback
on our initial cases has been so encouraging. These approvals combined with
the positive feedback will allow us to introduce the Trevo System to
customers in Europe and Canada in the near future."

About Concentric Medical

Concentric Medical is located in Mountain View, California and is the
global leader in the endovascular treatment of acute ischemic stroke. The
company manufactures and markets solutions for ischemic stroke: minimally
invasive devices that are delivered into the brain to restore blood flow by
removing blood clots that cause ischemic stroke. Concentric Medical's devices
are available in over 500 leading stroke centers around the world, and have
been the subject of several clinical studies. For more information about
Concentric Medical, please visit www.concentric-medical.com.

About the Trevo System

The Trevo System is an innovative, high-performing, easy-to-use thrombus
retrieval system. The main component of the Trevo System is a
stentriever(TM), a new generation of retrieval device that removes clots that
cause stroke.

About Acute Ischemic Stroke

Stroke is the third leading cause of death in the developed world and the
leading cause of serious long-term disability. Ischemic stroke represents
over 85% of strokes and occurs when a blockage or clot develops in one of the
arteries supplying blood to the brain. In 2004 the FDA cleared Concentric
Medical's Merci Retriever(R) for use in patients who are ineligible for
IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device
created a departure from the historic method of caring for stroke patients
and offered physicians and patients a long-awaited option for stroke
intervention.

    Media Contact: Scott Meggs, Corporate Counsel
                   +1-650-938-2100
                   strokeinfo@concentric-medical.com

Scott Meggs, Corporate Counsel of Concentric Medical, +1-650-938-2100, strokeinfo at concentric-medical.com